Recently added
This page was added on 04 June 2018.
Updates made
This page was updated on [date-counter-updated-date]. View history of updates
Registered as a booster in people aged ≥4 years.
dTpa-IPV — diphtheria-tetanus-acellular pertussis-inactivated poliovirus combination vaccine (reduced antigen formulation)
Each 0.5 mL monodose pre-filled syringe contains:
- ≥2 IU diphtheria toxoid
- ≥20 IU tetanus toxoid
- 8 µg pertussis toxoid
- 8 µg filamentous haemagglutinin
- 2.5 µg pertactin
- 40 D-antigen units inactivated poliovirus type 1 (Mahoney)
- 8 D-antigen units inactivated poliovirus type 2 (MEF-1)
- 32 D-antigen units inactivated poliovirus type 3 (Saukett)
Adsorbed onto 0.5 mg aluminium as aluminium hydroxide hydrate and aluminium phosphate.
Also contains traces of:
- formaldehyde
- polysorbate 80
- polymyxin
- neomycin
For Product Information and Consumer Medicine Information about Boostrix IPV vaccine visit the Therapeutic Goods Administration website.
Additional vaccine information
For detailed advice on vaccine dosage, administration, contraindications and precautions, and variations from product information, please visit the relevant disease chapter/s.